Search

Your search keyword '"Singal, Amit G."' showing total 207 results

Search Constraints

Start Over You searched for: Author "Singal, Amit G." Remove constraint Author: "Singal, Amit G." Publication Year Range This year Remove constraint Publication Year Range: This year
207 results on '"Singal, Amit G."'

Search Results

10. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

11. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

13. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

14. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC

18. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma

20. Racial and Ethnic Disparities in Liver Transplantation for Alcohol-associated Liver Diseases in the United States

21. Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals

23. Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial

24. Downstaging with Atezolizumab-Bevacizumab: A Case Series

27. Evidence and Choice: The BCLC Vision for Tailoring Clinical Decision-Making

29. Systemic Therapies for Hepatocellular Carcinoma in India

43. Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis

45. Artificial intelligence in liver cancer research: a scientometrics analysis of trends and topics

46. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis

47. Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.

48. Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

49. Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.

50. Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC).

Catalog

Books, media, physical & digital resources